表紙
市場調査レポート

膣萎縮 (萎縮性腟炎) :パイプライン製品の分析

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 326371
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
膣萎縮 (萎縮性腟炎) :パイプライン製品の分析 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 54 Pages
概要

膣萎縮は萎縮性腟炎とも呼ばれ、エストロゲンの減少から膣壁が薄くなり、乾燥し、炎症を起こした状態をいいます。乾燥、膣分泌物、掻痒、排尿時灼熱感、尿意切迫、尿路感染症、尿失禁などの兆候および症状があります。喫煙などが素因であり、局所用 (膣用) エストロゲン剤、全身用エストロゲン剤の利用などの治療法があります。

当レポートでは、世界における膣萎縮 (萎縮性腟炎) のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要 (製品概要、機能メカニズム、研究開発の進展状況) 、最新の業界動向などを調査した結果をお届けします。

イントロダクション

  • 調査範囲

膣萎縮 (萎縮性腟炎) の概要

治療薬の開発

  • パイプライン製品の概要

膣萎縮 (萎縮性腟炎):企業で開発中の治療薬

膣萎縮 (萎縮性腟炎):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

膣萎縮 (萎縮性腟炎):企業で開発中の製品

膣萎縮 (萎縮性腟炎) の治療薬開発に従事している企業

  • EndoCeutics, Inc.
  • Foamix Pharmaceuticals Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Mithra Pharmaceuticals S.A.
  • PEPTONIC medical AB
  • TherapeuticsMD, Inc.

膣萎縮 (萎縮性腟炎):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

膣萎縮 (萎縮性腟炎):最近のパイプライン動向

膣萎縮 (萎縮性腟炎):休止中のプロジェクト

膣萎縮 (萎縮性腟炎):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8069IDB

Summary

Global Markets Direct's, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016', provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)
  • The report reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vaginal Atrophy (Atrophic Vaginitis) therapeutics and enlists all their major and minor projects
  • The report assesses Vaginal Atrophy (Atrophic Vaginitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vaginal Atrophy (Atrophic Vaginitis) Overview
  • Therapeutics Development
    • Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview
  • Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies
  • Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
    • EndoCeutics, Inc.
    • Foamix Pharmaceuticals Ltd.
    • Ligand Pharmaceuticals, Inc.
    • Mithra Pharmaceuticals S.A.
    • PEPTONIC medical AB
    • TherapeuticsMD, Inc.
  • Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Estetrol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • estradiol hemihydrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lasofoxifene tartrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxytocin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prasterone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TX-004HR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates
  • Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
  • Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
      • Apr 02, 2016: TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy at ENDO 2016
      • Apr 02, 2016: TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy at ENDO 2016
      • Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study
      • Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting
      • Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting
      • Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting
      • Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause
      • Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR
      • Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals S.A., H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H1 2016
  • Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top